Maximus Review

FDA action on record

FDA advised Maximus of significant violations identified during a review of its promotional material, in the same round of letters addressing false or misleading claims about compounded GLP-1 products.

• Entity: Maximus Health, Inc. dba Maximus
• Action: FDA warning letter (MARCS-CMS 730095)
• Date: June 8, 2026

A warning letter is FDA's stated position that violations occurred. It is not a court finding, a recall, or a determination that any patient was harmed, and these letters concerned marketing claims about compounded GLP-1 products rather than a specific batch of medication. Companies often respond and correct the cited material. We publish this so you can weigh it yourself — read the letter and check the provider's current status before deciding.